Syncona — Full Portfolio

Forcefield Therapeutics develops cardioprotective proteins for the treatment of cardiac disease, with an initial focus on myocardial infarction (heart attack).

BiotechHealthtechMedical Devices

John

Co-investorsRoche Venture Fund

iOnctura is a clinical-stage drug development company developing precision oral small-molecule therapies targeting the tumor-stroma-immune interface, with a pipeline including roginolisib and cambritaxestat in cancers such as uveal melanoma and pancreatic cancer.

BiotechDeep TechHealthtechMedical Devices

Catherine Pickering(Co-Founder & CEO)inLars van der Veen(Co-Founder & CSO)inMichael Lahn(CMO)inElizabeth Holt(CBO)inSteven Sciuto(CFO)inMichelle Tsai(COO)in

Co-investorsInkef3B Future Health FundM VenturesVI PartnersXGEN Venture

Ambagon develops small molecule stabilizers of 14-3-3 protein complexes to modulate disease-related protein interactions, targeting therapeutic areas including cancer, metabolic disorders, neurodegenerative and infectious diseases.

BiotechDeep TechMedical DevicesEindhoven, US

Christian Ottmann(Executive Officer)Josh Seidenfeld(Executive Officer)Michelle Arkin(Director)Nancy Pryer(Executive Officer)Margarita Chavez(Director)Bryan Miller(Executive Officer)

Board seatRoel Bulthuis· per SEC Form D · $85M raise · filed Jun 2022

Co-investorsDroia VenturesMission BiocapitalMRL Ventures FundNextech InvestInkefRA Capital

BiotechStevenage, Hertfordshire

Ian Pitfield(Executive Officer)David Fellows(Director)Jessica Stitt(Executive Officer)Renee Gala(Director)Khurem Farooq(Executive Officer)Edward Lang(Executive Officer)

Board seatChris Hollowood· per SEC Form D · $148M raise · filed Apr 2021

Co-investorsForbionSofinnova Ventures

Clinical-stage biotech developing neoantigen-targeted T cell receptor (TCR) therapies for cancer; acquired by AstraZeneca.

BiotechNew York, US

Carsten Linnemann, PhD(Executive Officer, Director, Promoter)Antonius N.M. Schumacher(Director)Fei Chen(Director)

BoardDavid M. Tanen(Director, Promoter)Helen Kim(Director)

Board seatElisa Petris· per SEC Form D

Co-investorsEcoR1 CapitalJeito CapitalVida VenturesTPG

BiotechCambridge, US

Robert Connelly(Executive Officer, Director)Garry Menzel(Executive Officer)Jeff Moore(Executive Officer)

BoardJohn Mendlein(Director)David Berry(Director)inNoubar Afeyan(Director)in

Board seatPaul Sekhri· per SEC Form D · $12M raise · filed Sep 2022

Co-investorsFlagship Pioneering

QurAlis develops precision therapies for amyotrophic lateral sclerosis (ALS) and related neurodegenerative diseases by targeting specific disease-causing genetic drivers and molecular mechanisms.

BiotechDeep TechMedical DevicesCambridge, US

Kevin Eggan(Co-founder)Roet(Co-founder)Woolf(Co-founder)Kasper Roet(Director, Executive Officer, Promoter)inShafique Virani(Executive Officer)Jason Brown(Mr. Brown is the Chief Financial Officer of the Issuer.)

Board seatRoel Bulthuis· per SEC Form D · $10M raise · filed Sep 2022

Co-investorsDroia VenturesMC Healthcare VenturesMission BiocapitalMitsui Global InvestmentSanofi VenturesSV Health Investors+7 more

Anaveon develops engineered antibodies targeting immune system regulatory nodes to treat autoimmune diseases by selectively eliminating or reprogramming pathogenic immune cells.

BiotechBasel, CH

Thaminda(Chief Business Officer)inLaetitia Pouzol(Chief Scientific Officer)in

Co-investorsNovartis Venture FundPfizer Venture InvestmentsPontifax Venture Capital

Biopharmaceutical company developing CAR T-cell therapies for blood cancers, with FDA approval for AUCATZYL® (obe-cel) for relapsed/refractory B-cell acute lymphoblastic leukemia.

Co-investorsAdvent Life SciencesOxford Science Enterprises

BiotechCambridge, US

Chad A. Cowan(Executive Officer, Director)Leandro Vetcher(Executive Officer)Daniel Vasella(Director)Jim Glasheen(Executive Officer, Director)Neil White(Director)

BoardMartin Murphy(Director)

Co-investorsBain Capital Life SciencesCasdin CapitalVenrock Healthcare Capital Partners

Co-investorsSofinnova VenturesCambridge Innovation Capital

Co-investorsCambridge Innovation Capital

Co-investorsNew Enterprise Associates (NEA)

OMass uses native mass spectrometry, proprietary biochemistry and custom chemistry to study drug targets and their interactions with their native biological environment outside the confounding complexity of the cell.

BiotechDeep TechHealthtech

Ros Deeganin

Co-investorsGV (Google Ventures)Oxford Science EnterprisesSanofi Ventures

Purespring is a precision nephrology company developing podocyte-targeted gene therapies for kidney diseases, using its GlomThera platform to deliver genetic treatments directly to kidney cells.

BiotechHealthtechMedical Devices

Co-investorsSofinnova PartnersBritish Patient CapitalForbionGilde Healthcare

Clinical stage company transforming lives in immune mediated disease

Co-investorsAlbionVCJeito CapitalSV Health Investors

Resolution Therapeutics develops Regenerative Macrophage Therapy, a cell therapy for patients with end-stage liver disease intended to help damaged livers recover and slow disease progression.

BiotechHealthtech

Spur Therapeutics develops gene therapies aiming to halt the progression of chronic conditions with a single dose of genetic medicine.

BiotechHealthtech

Co-investorsAlbionVCUCL Technology Fund